direct factor Xa inhibitors

systematic review meta-analysis network meta-analysis

Select acute coronary syndromeatrial fibrillationcardiovascular preventionthrombosis preventionvenous thrombosis All type of patientsecondary prevention       direct factor Xa inhibitorsNOACoral direct thrombin inhibitororal factor Xa inhibitororal factor Xa inhibitors apixabandabigatranedoxabanotamixabanrivaroxabanximelagatran vs discontinuationvs placebo and controlvs placebo or controlvs anticoagulantvs antiplatelet drugsvs Low molecular weight heparinvs UFH      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	Major bleeding (20)All cause death (19)major or clinically relevant non-major bleeding (17)Coronary event (11)proximal DVT (10)total VTE and all-cause mortality (9)cardiovascular events (8)Cardiovascular death (8)myocardial infarction (fatal and non fatal) (8)major VTE (fatal and non fatal DVT,PE) (8)Fatal bleeding (7)ischemic stroke (7)Deep vein thrombosis (7)Symptomatic venous thromboembolism (DVT, PE) (7)stroke (fatal and non fatal) (7)non-fatal pulmonary embolism (6)distal DVT (6)any bleedings (5)Symptomatic deep-vein thrombosis (5)Haemmorhagic stroke (5)thrombo-embolic event (cerebral or systemic) (5)Gastrointestinal major bleeding (5)asymptomatic DVT (4)Fatal stroke (4)systemic thrombo-embolic complication (4)cardiac event (fatal and non fatal ) (3)Lifethreatening major bleeding (3)stent thrombosis (2)major or minor bleeding (2)VTE (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	Major bleeding	All cause death
acute coronary syndrome
apixaban
APPRAISE-1 (10mg od), 2009      NCT	apixaban	placebo			Low risk of bias	negative
APPRAISE-1 (2.5 mg bid), 2009      NCT	apixaban	placebo			Low risk of bias	negative
APPRAISE 2, 2011      NCT	apixaban	placebo			Low risk of bias	negative
dabigatran
REDEEM, 2009    NCT	dabigatran	placebo			Low risk of bias	negative
otamixaban
SEPIA-ACS1 TIMI 42, 2009    NCT	otamixaban	unfractionated heparin			Low risk of bias	suggesting
rivaroxaban
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011      NCT	rivaroxaban 2.5mg	placebo			Low risk of bias	suggesting
ATLAS ACS-TIMI 46 (2.5mg), 2009      NCT	rivaroxaban 2.5mg	placebo			Low risk of bias	negative
ATLAS ACS 2 - TIMI 51 (5mg), 2011      NCT	rivaroxaban 5mg	placebo				suggesting
ATLAS ACS-TIMI 46 (5mg), 2009      NCT	rivaroxaban 5mg	placebo			Low risk of bias	negative
ximelagatran
ESTEEM, 2003	ximelagatran	placebo			Exploratory	-
atrial fibrillation
apixaban
AVERROES, 2011        NCT	apixaban	aspirin	ineligible for VKA		Low risk of bias	suggesting
ARISTOTLE, 2011        NCT	apixaban	warfarin standard dose			Low risk of bias	conclusive
phase 2 apixaban    NCT	apixaban	warfarin standard dose			Exploratory	-
edoxaban
Weitz (edoxaban phase 2)    NCT	edoxaban	warfarin standard dose			Exploratory	-
phase 2 edoxaban    NCT	edoxaban	warfarin standard dose			Exploratory	-
ENGAGE-AF TIMI 48 High dose, 2013    NCT	edoxaban high dose	warfarin standard dose			Low risk of bias	suggesting
rivaroxaban
ROCKET-AF, 2010        NCT	rivaroxaban	warfarin standard dose			Low risk of bias	suggesting
cardiovascular prevention
rivaroxaban
COMPASS (rivaroxaban alone), 2017    NCT	rivaroxaban	aspirin	secondary prevention			-
COMPASS (rivaroxaban + aspirin), 2017      NCT	rivaroxaban + aspirin	aspirin	secondary prevention		Low risk of bias	-
thrombosis prevention
apixaban
ADVANCE 3, 2010    NCT	apixaban	enoxaparin	hip surgery		Low risk of bias	suggesting
ADVANCE 2, 2010      NCT	apixaban	enoxaparin (europe regimen)	knee surgery		Low risk of bias	suggesting
APROPOS 2.5mg, 2007    NCT	apixaban	enoxaparin (US regimen)	knee surgery		Low risk of bias	negative
ADVANCE-1, 2008      NCT	apixaban	enoxaparin (US regimen)	knee surgery		Low risk of bias	suggesting
edoxaban
STARS J-V    NCT	edoxaban	enoxaparin (short duration)	hip surgery		Low risk of bias	suggesting
rivaroxaban
RECORD 1, 2008      NCT	rivaroxaban	enoxaparin	hip surgery		Low risk of bias	suggesting
RECORD 3, 2008    NCT	rivaroxaban	enoxaparin (europe regimen)	knee surgery		Low risk of bias	suggesting
ODIXa-HIP 10mg, 2006	rivaroxaban	enoxaparin (short duration)	hip surgery		Low risk of bias	suggesting
RECORD 2, 2008    NCT	rivaroxaban (long duration)	enoxaparin (short duration)	hip surgery		Low risk of bias	suggesting
ODIXa-KNEE, 2005	rivaroxaban	enoxaparin (US regimen)	knee surgery		Low risk of bias	negative
RECORD 4, 2009    NCT	rivaroxaban	enoxaparin (US regimen)	knee surgery		Low risk of bias	suggesting
venous thrombosis
ximelagatran
THRIVE III, 2003	ximelagatran	discontinuation			Low risk of bias	suggesting